Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repatha in stage IV-V chronic kidney disease
NCT04510844Phase 4Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in hypercholesterolemia, sponsored by NYU Langone Health. Planned start Mar 2021; status: withdrawn.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04510844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510844.